Denali Therapeutics and Royalty Pharma Agree to $275 Million Royalty Funding Deal for Tividenofusp Alfa.

Denali Therapeutics and Royalty Pharma have entered a $275 million royalty funding agreement based on future net sales of tividenofusp alfa, a treatment for mucopolysaccharidosis type II (MPS II, or Hunter syndrome). The agreement supports Denali's ability to launch tividenofusp alfa and advance its development programs. Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa from Denali.